Pharmaceuticals 2010, 3(4), 810-838; doi:10.3390/ph3040810
Review

Synthetic Medicinal Chemistry in Chagas’ Disease: Compounds at The Final Stage of “Hit-To-Lead” Phase

Received: 1 February 2010; in revised form: 15 March 2010 / Accepted: 19 March 2010 / Published: 25 March 2010
(This article belongs to the Special Issue Tropical Medicine)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: Chagas’ disease, or American trypanosomosiasis, has been the most relevant illness produced by protozoa in Latin America. Synthetic medicinal chemistry efforts have provided an extensive number of chemodiverse hits at the “active-to-hit” stage. However, only a more limited number of these have been studied in vivo in models of Chagas’ disease. Herein, we survey some of the cantidates able to surpass the “hit-to-lead” stage discussing their limitations or merit to enter in clinical trials in the short term.
Keywords: Chagas’ disease; “hit-to-lead”; drug-likeness
PDF Full-text Download PDF Full-Text [638 KB, uploaded 25 March 2010 10:07 CET]

Export to BibTeX |
EndNote


MDPI and ACS Style

Cerecetto, H.; González, M. Synthetic Medicinal Chemistry in Chagas’ Disease: Compounds at The Final Stage of “Hit-To-Lead” Phase. Pharmaceuticals 2010, 3, 810-838.

AMA Style

Cerecetto H, González M. Synthetic Medicinal Chemistry in Chagas’ Disease: Compounds at The Final Stage of “Hit-To-Lead” Phase. Pharmaceuticals. 2010; 3(4):810-838.

Chicago/Turabian Style

Cerecetto, Hugo; González, Mercedes. 2010. "Synthetic Medicinal Chemistry in Chagas’ Disease: Compounds at The Final Stage of “Hit-To-Lead” Phase." Pharmaceuticals 3, no. 4: 810-838.

Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert